Skip to main content

Table 3 Demographic and clinical parameters according to tertiles of circulating DPP4 activity in diabetic patients

From: The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus

Parameters DPP4 (pmol/min/mL) p value
<5060 5060-6208 >6208
Age (years) 65 ± 9.1 66.2 ± 7.1 64.7 ± 9.7 0.836
Male/female (%) 59/41 68/32 61/39 0.657
BMI (Kg/m2) 32 ± 6.4 28.5 ± 4.5 29.4 ± 4.5 0.086
SBP (mmHg) 140 ± 17 136 ± 23.8 141 ± 23.9 0.767
DBP (mmHg) 80 (70-80) 70 (60-80) 75 (70-80) 0.300
MBP (mm Hg) 97.8 ± 8 93.6 ± 13.8 97.8 ± 13.4 0.395
PP (mmHg) 63.3 ± 17.5 64.1 ± 18.4 64.3 ± 23.2 0.984
HbA1c (%) 6.5 (6.1-7.4) 6.5 (5.9-7.2) 6.9 (6-7.9) 0.555
Fasting glucose (mg/dL) 112 (100-129) 113 (106-169) 117 (109-171) 0.265
Comorbidities, (n, %)     
Hypertension 22, 82 22, 79 24, 85 0.997
Hypertriglyceridemia 5, 19 6, 21 7, 25 0.811
Hypercholesterolemia 4, 15 9, 32 10, 36 0.440
Obesity 16, 60 9, 32 14, 50 0.230
CKD 6, 22 5, 17 4, 14 0.409
Treatment (n, %)     
Antidiabetic agents     
Metformin 9, 33 4, 14 12, 43 0.064
Sulfonylureas 7, 26 7, 26 4, 14 0.199
Other oral anti-diabetic drugs 5, 19 7, 26 10, 36 0.418
Insulin 6, 22 7, 25 10, 36 0.664
Anti-hypertensive agents     
ACEi/ARAs 17, 63 15, 53 17, 61 0.634
Diuretics 6, 22 7, 25 7, 25 0.938
Ca2 + -antagonists 3, 11 9, 32 7, 25 0.104
Beta-blockers 7, 26 7, 25 6, 21 0.888
Other pharmacological agents     
Statins 15, 55 18, 64 15, 57 0.824
Anti-coagulants 5, 19 4, 14 5, 19 0.910
Anti-aggregants 15, 56 15, 53 14, 50 0.902
  1. BMI means body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure; PP, pulse pressure; HbA1c, glycosylated haemoglobin; CKD, chronic kidney disease; ACEi, angiotensin converting enzyme inhibitor; ARA, angiotensin II type 1 receptor antagonist. Values are expressed as mean ± SD or median (interquartile range), and categorical variables as numbers and percentages.